企業プロフィール
Olema Pharmaceuticals, Inc. 株価・ニュース・カタリスト
- ティッカー:
- OLMA
- 取引所:
- NASDAQ
- セクター:
- Biopharma
- 所在地:
- United States
株価パフォーマンス
10.77 USD (+1.32%)
終値
最終更新: 2026年8月17日
934M USD
時価総額
株価変動の要因
As of Aug 17, 2026, OLMA closed up 1.32% at $10.77. No new same-company headline was identified in the current news window.
企業概要
Endocrine-Driven Cancer Company
Olema Oncology develops targeted therapies based on estrogen receptor biology, nuclear receptors, and resistance mechanisms in breast cancer.
Palazestrant
Palazestrant is an oral complete estrogen receptor antagonist being studied as monotherapy and in combinations for ER-positive, HER2-negative breast cancer.
OP-3136
OP-3136 is an oral KAT6 inhibitor intended to complement endocrine therapy and address transcriptional drivers of resistance.
今後のカタリスト
- Initiation of the Phase 1b/2 study of OP-3136 with darolutamide in metastatic castration-resistant prostate cancer in the fourth quarter of 2026.
- Topline results from the Phase 3 OPERA-01 palazestrant study in the first quarter of 2027.
最近のニュース
- 01
- 02
- 03
- 04
- 05
類似銘柄
事業成熟度、治療領域、カタリスト傾向が近い同業銘柄です。